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REVIEWARTICLENatural Medicines for Psychotic Disorders
A Systematic ReviewH.J. Rogier Hoenders, MD, PhD,* Agna A. Bartels-Velthuis, PhD,*† Nina K. Vollbehr, MSc,*
Richard Bruggeman, MD, PhD,† Henderikus Knegtering, MD, PhD,†‡§
and Joop T.V.M. de Jong, MD, PhD||¶Abstract: Patients with psychotic disorders regularly use natural medicines,
although it is unclear whether these are effective and safe. The aim of this study
was to provide an overview of evidence for improved outcomes by natural medi-
cines. A systematic literature search was performed throughMedline, PsycINFO,
CINAHL, and Cochrane until May 2015. In 110 randomized controlled trials,
evidence was found for glycine, sarcosine, N-acetylcysteine, some Chinese
and ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6 to improve psy-
chotic symptoms when added to antipsychotics. Ginkgo biloba and vitamin B6
seemed to reduce tardive dyskinesia and akathisia. Results on other compounds
were negative or inconclusive. All natural agents, except reserpine, were well
tolerated. Most study samples were small, study periods were generally short,
and most results need replication. However, there is some evidence for beneficial
effects of certain natural medicines.
Key Words: Psychosis, natural products, complementary medicine
(J Nerv Ment Dis 2018;206: 81–101)
D espite much progress in treatment options in the last century, thepharmacological treatment of psychotic disorders is often unsatis-
factory, as expressed in persistent positive, negative, cognitive and affective
symptoms, and problems in social functioning (Kane and Correll, 2010).
Psychotic symptoms are often only partially resolved (Rummel-Kluge
et al., 2010), especially cognitive and negative symptoms (Buckley and
Stahl, 2007). Apart from clozapine, second-generation antipsychotics are
generally as effective as first-generation antipsychotics for positive
symptoms, but the promise of greater efficacy for negative symptoms
has not been fulfilled (Leucht et al., 2012). Many patients continue
experiencing persistent symptoms and relapses during treatment with
antipsychotics, particularly when they fail to adhere to prescribed
medications (Van Os and Kapur, 2009). Psychiatric medication adherence
is a problem because many patients do not want them or consider them
unnecessary (Cooper et al., 2007), or experience undesired adverse
effects (Pai and Vella, 2012). For antipsychotics, these adverse effects
include weight gain, sexual dysfunction, glycemic and lipid dysfunction,
extrapyramidal symptoms (EPS), and sedation (Stahl, 2008).
Many patients with psychotic disorders use nonconventional
medicines or treatments in the hope of decreasing undesired adverse*Lentis, Center for Integrative Psychiatry; †University of Groningen, UniversityMedical
Center Groningen, University Center for Psychiatry, Rob Giel Research Center;
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Center Groningen, Neuroimaging Center; ||University of Amsterdam, Amsterdam,
the Netherlands; and ¶Boston School of Medicine, Boston, Massachusetts.
Send reprint requests to H.J. Rogier Hoenders, MD, PhD, Lentis, Center for Integrative
Psychiatry, Hereweg 80, 9725 AG Groningen, the Netherlands.
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Copyright © 2018 The Author(s). Published byWolters Kluwer Health, Inc. This is an
open-access article distributed under the terms of the Creative Commons
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it is permissible to download and share the work provided it is properly cited.
The work cannot be changed in any way or used commercially without permis-
sion from the journal.
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The Journal of Nervous and Mental Disease • Volume 206, Number 2effects or a more successful recovery (Hazra et al., 2010; Stevinson,
2001). Nonconventional medicine includes therapeutic lifestyle changes
and complementary and alternative medicine (CAM) (Hoenders, 2013).
Complementary medicine comprises diagnostics, treatments, and pre-
vention strategies based on theories accepted in biomedicine and substan-
tiated by some scientific evidence (two or more randomized controlled
trials [RCTs]), but for various (cultural or practical) reasons are no part
of biomedicine (Hoenders et al., 2011). Alternative medicine comprises
diagnostics, treatments, and prevention strategies using other than the ba-
sic concepts of biomedicine. So far, there is little proof for the efficacy of
the latter treatments and/or considerable controversy about their scientific
validation (Lake, 2007). Natural medicine is part of complementarymed-
icine, using agents produced by living organisms (plant, tree, seed, vege-
table, fruit, animal, and human) instead of nonnatural (i.e., chemical)
agents only being obtained from laboratory experiments (Porter, 1998).
Some patients prefer natural medicines, assuming that natural is better
and will cause fewer adverse effects. This is obviously not (always) true,
as the natural environment contains agents that can be toxic to humans.
The molecular structure and dosage of a substance rather than its source
determine its effect on human health (Topliss et al., 2002). Besides,
herbal medicines can cause undesired effects including interactions with
prescription medication (Ernst, 2003a, 2003b).
Hazra et al. (2010) reported a lifetime and 1-year prevalence rate
of CAM use in Canadian psychotic outpatients of 88% and 68%, re-
spectively. A major difficulty these patients encounter is the heteroge-
neity in treatment options with CAM, ranging from possibly
interesting agents to useless, or even dangerous, ones (Ernst, 2003b).
For instance, the concomitant use of antipsychotics and Chinese herbs
was found to induce significantly improved clinical outcomes com-
pared with antipsychotics only (Rathbone et al., 2007). However, a
small but significant number of patients concomitantly treated with
Chinese herbs have a greater risk of developing worse outcomes (Zhang
et al., 2011b).
In recent years, patients' preferences and views have received
more attention in making treatment choices (e.g., shared decision mak-
ing [Elwyn et al., 2000] and “patient-centered care” [Gill, 2013]). The
introduction of patient's choice in deciding which antipsychotic to
choose has been proposed (Morrison et al., 2012). However, it is diffi-
cult for both patients and physicians to make informed decisions in the
absence of reliable information on the emerging evidence for CAM or
natural medicine. Considering its high usage in psychotic patients, there
is an urgent need for readily available scientific information.
This article reviews the literature on the efficacy and safety of
natural medicines for psychotic disorders.REVIEW
Materials and Methods
Literature Search and Study Selection
Studies were identified by a literature search in Medline,
PsycINFO, CINAHL, and Cochrane, until May 2015, in accordance, February 2018 www.jonmd.com 81
TABLE 1. Sources of Literature Retrieval and Included Number of
Studies
Database Trials Reviews Total
Medline 511 629 1140
CINAHL 62 22 84
PsycINFO 245 129 374
Cochrane 253 20 273
Total 1069 800 1871
Total deduplicated 1467
Hoenders et al. The Journal of Nervous and Mental Disease • Volume 206, Number 2, February 2018with the Medline RCT filter. The search terms (MeSH Thesaurus and
free search terms) used were schizophrenia, psychosis, psychoses, psy-
chotic (disorder), schizophreniformAND (R)CT, review AND comple-
mentary medicines, herbs, vitamins, supplements (search terms, inFIGURE 1. Flowchart of study selection.
82 www.jonmd.comalphabetical order: alpha lipoic acid [ALA], artemisinin, ascorbic acid,
Ayurveda, brahmyadiyoga, branched-chain amino acids [BCAA],
Chinese herbs, D-cycloserine, D-serine, daotan decoction, dehydroepi-
androsterone [DHEA], docosahexaenoic acid [DHA], eicosapentaenoic
acid [EPA], estradiol, fatty acid, fish oil, folic acid, ginkgo biloba,
glycine, jiawei lingguizhugan tang, jieyu anshen decoction,
L-stepholidine, L-theanine, manganese, methylfolate, N-acetylcysteine
[NAC], N-methylglycine, niacine, omega-3, orengedokuto, rauwolfia
serpentina, saikokaryukotsuboreito, sarcosine, sarsasapogenin, sele-
nium, shakuyakukanzoto, shuizhi dahuang mixture, suo quan,
tongdatang serial recipe [TDT], traditional Chinese medicine [TCM],
vitamin B complex, vitamin B3, vitamin C, vitamin D, vitamin E, and
zinc). After systematic deduplication, 1465 hits (abstracts) were
retrieved (Table 1).
Next, abstracts about the following topics were included: a) ef-
fects of natural medicines on psychotic symptoms in schizophrenia
spectrum nonaffective disorders and b) effects of natural medicines on
the adverse effects of antipsychotics. Those excludedwere a) nonrandomized© 2018 Wolters Kluwer Health, Inc. All rights reserved.
The Journal of Nervous and Mental Disease • Volume 206, Number 2, February 2018 Natural Medicines for Psychosis(controlled) trials; b) mechanism studies exploring the effects of natural
medicines; c) animal studies; d) affective disorders/other disorders/no
disorder/(relapse) prevention; e) conference abstracts; f) book chapters; g)
clinical trial registrations; h) comments, addenda, corrigenda, and
letters; i) non-English languages (e.g., Chinese, Japanese, Hebrew,
German, and Spanish); and (j) duplicate hits that had not been removed
systematically. Second, two authors (H.J.R.H. and A.A.B.V.) indepen-
dently indicated whether papers—based on the abstracts—should (pos-
sibly) be included. Consultation followed about dubious cases and in
case of discordance. Thereupon, 427 studies remained, of which the full
papers on RCTs were retrieved and studied. Of these, another 160 were
excluded. A flowchart of the study selection is presented in Figure 1.
We found 147 reviews and checked whether RCTs in their reference
lists matching our inclusion criteria were included. Eight RCTs with a
Jadad score of 3 or higher (see paragraph on risk of bias assessment and
Table 2) found through cross-references were added. Eighteen RCTs were
excluded because of a Jadad score less than 3. The reviews (not shown
in Table 3) will be contrasted to our findings in the Discussion section.Classification of Agents
The RCTs included were divided into six groups based on sup-
posed underlying mechanisms of action (Table 3). For a good grasp
of the results, we briefly present the working mechanisms of the
agents from five groups (not from the group “other substances”).
(i) Omega-3 fatty acids. Polyunsaturated fatty acids (PUFAs) are
essential for brain functioning (Tsalamanios et al., 2006). They have
multiple important biological roles, including membrane functioning,
neurotransmission, signal transduction, and eicosanoid synthesis. Re-
search suggests that PUFA level reduction is related to schizophrenia
(Berger et al., 2006). Concordant with these findings, omega-3 PUFA
may have positive effects in the treatment of schizophrenia (Emsley
et al., 2002; Peet, 2008).
(ii) Glutamate. Besides dopamine, glutamate is thought to play a
role in schizophrenia (Tsai and Lin, 2010). On the basis of the hypoth-
esis that the glutamatergic system may be compromised in schizophre-
nia, the use of N-methyl-D-aspartate (NMDA) receptor modulators may
compensate for alterations in the glutamate system (Singh and Singh,
2011). Agents with coagonistic properties to (glutaminergic) NMDA
receptors are glycine (full, endogenous agonist), D-serine (full, endoge-
nous agonist), D-cycloserine (partial, exogenous agonist), D-alanine
(partial, endogenous agonist), and sarcosine (= methylglycine,
acting as a reuptake inhibitor of glycine and source of glycine).
The glycine transporter-1 (GlyT-1) plays a pivotal role inTABLE 2. Jadad Scale for Assessing the Quality of RCTs
Item Des
Randomization Was the study described as randomize
as randomly, random, and randomi
Was the method to generate the seque
appropriate (table of random numb
Was the method to generate the seque
inappropriate (patients were allocat
birth, hospital number, etc)?
Blinding Was the study described as double bli
Was the method of double blinding d
(identical placebo, active placebo, d
Was the study described as double bli
inappropriate (e.g., comparison of t
An account of all patients Was there a description of withdrawal
© 2018 Wolters Kluwer Health, Inc. All rights reserved.maintaining the glycine concentration within synapses at a
subsaturating level. Sarcosine is a GlyT-1 inhibitor, meaning that its
presence results in increased glycine concentrations. Lower cerebral
glycine levels are suggested to be found in patients with schizophrenia.
The administration of sarcosine is therefore proposed to relieve symp-
toms of schizophrenia when added to nonclozapine antipsychotics
(Lane et al., 2006). Whereas the mechanisms of NAC are now begin-
ning to be understood, NAC is probably exerting benefits beyond being
a precursor to the antioxidant glutathione, also modulating glutamater-
gic, neurotropic, and inflammatory pathways (Dean et al., 2011).
(iii) Eastern (Chinese and ayurvedic) herbs. Eastern herbs are
provided in the context of treatment with complete systems of
medicine that evolved over thousands of years, such as TCM and
Ayurveda. These treatments include prescription of herbal com-
pounds, massage, diet, acupuncture, and the regulation of lifestyle
(Clifford, 1994; Kaptchuck, 2000). Most clinical studies were per-
formed on acupuncture (beyond the scope of this review) and on
herbal compounds.
(iv) B vitamins. Nobel laureate Linus Pauling proposed a way of
understanding and treating psychiatric disorders by correcting
malfunctions in the body's chemistry, calling this approach “orthomo-
lecular psychiatry” (Pauling, 1968). His idea was partly built on studies
by Osmond and Hoffer (1962) and Hoffer and Osmond (1964),
reporting good results when treating patients with schizophrenia with
large doses of vitamins, especially vitamin B3. Hoffer (1971, 1972)
published twomore positive results with B vitamins. However, attempts
to replicate his findings seem to have failed (Ban and Lehmann, 1975;
Wittkopp and Abuzzahab, 1972). The contradicting findings may be
explained because vitamine B is suggested to be effective in early psy-
chosis but not in chronic schizophrenia (Hoffer and Osmond, 1964).
One of the proposed mechanisms is abnormal one-carbon metabolism
due to vitamin deficiencies (Hoffer, 2008). Variable levels of the com-
ponents of one-carbon metabolism (folic acid [= vitamin B9] and vita-
min B12) and consequently altered levels of homocysteine and
phospholipid DHA have been reported both in medicated patients and
in medication-naive first-episode psychotic patients (Kale et al.,
2010). Folate status in patients with schizophrenia correlates inversely
with negative symptoms (Goff et al., 2005).
(v) Antioxidants. Oxygen is essential in life but also generates re-
active molecules (so-called free radicals) throughout the body. These
free radicals are potentially harmful because they can damage essential
molecules such as DNA and the enzymes necessary for proper cell
functioning. Antioxidants may capture these reactive free radicals and
convert them back to less reactive forms of the molecules (Singhcription Scoring
d (this includes the use of words such
zation)?
1 point
nce of randomization described and
ers, computer generated, etc)?
+1 point
nce of randomization described
ed alternately, or according to date of
−1 point
nd? 1 point
escribed and was it appropriate
ummy, etc)?
+1 point
nd but the method of blinding was
ablet vs injection with no double dummy)?
−1 point
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The Journal of Nervous and Mental Disease • Volume 206, Number 2, February 2018 Natural Medicines for Psychosiset al., 2010). Research suggests that oxidative damage (maybe due to
defective enzyme systems) may contribute to the course and outcome
of schizophrenia (Fendri et al., 2006; Mahadik and Mukherjee, 1996;
Mahadik et al., 2001) and is already present in patients with first-
episode psychosis (Flatow et al., 2013).
Ascorbic acid (vitamin C), an antioxidant vitamin, plays an im-
portant role in protecting free radical-induced damage in the body. It
is present in brain tissue and dopamine-dominant areas in higher con-
centrations compared with other organs (Harrison and May, 2009).
Ginkgo biloba, an extract of the leaves of the ginkgo biloba tree, is
also suggested to have antioxidant properties (Maclennan et al.,
2002), improving brain circulation at the microvascular level (Kuboto
et al., 2001; Sun et al., 2003; Yan et al., 2008) and, thus, improving
outcome in psychosis.
Long-term treatment with antipsychotics is associated with a va-
riety of movement disorders, including tardive dyskinesia (TD). Both
dopamine receptor supersensitivity and oxidative stress-induced neuro-
toxicity in the nigrostriatal system are suggested to be involved in its
pathogenesis (Kulkarni and Naidu, 2003). The pineal hormone melato-
nin is a potent antioxidant and attenuates dopaminergic activity in the
striatum and dopamine release from the hypothalamus (Shamir
et al., 2001). Thus, treatment with antioxidative agents may have a
beneficial effect for both treatment of psychotic symptoms and pre-
vention of TD. Vitamin E has been suggested for TD because it is a
lipid-soluble antioxidant that decreases free radical formation
(Herrera and Barbas, 2001).
Risk of Bias Assessment
Two assessors (A.A.B.V. and N.K.V.) independently rated the
methodological quality of the eligible RCTs using the Jadad scale
(Jadad et al., 1996). Interrater agreement on the Jadad scores before
consensus discussion amounted to 0.83. Besides, H.J.R.H. indepen-
dently rated a random selection of 17 papers (15%) from the selected
RCTs. Interrater agreement of all three assessors was 0.71. Any scoring
disagreements between the assessors were resolved through consensus
discussion between these three authors. The 110 RCTs with a Jadad
score of 3 or higher were included in the current review, categorized
into six groups (see the Classification of agents section).
For each of the 110 studies fulfilling the selection criteria, the
following assessments were made: which natural agent was used; was
this combined with antipsychotics, and if so, which antipsychotics and
what dosage; the effect of the natural agent on negative, positive, cognitive,
depressive, and general symptoms and on adverse effects of antipsychotics;
possible adverse effects of the natural agent; number of participants in the
study; control group characteristics; number of dropouts; study duration;
and Jadad score. The results are shown in Table 3.
Results
In total, 110 RCTs that matched the inclusion criteria were identi-
fied. Detailed effects are given in Table 3. Most of the studies were per-
formed in the United States, followed by (in decreasing order) Israel,
Canada, Taiwan, China, India, United Kingdom, Australia, Iran, South
Africa, Switzerland, the Netherlands, Austria, Ireland, Korea, and Norway.
(i) Omega-3 Fatty Acids
Eleven RCTs on omega-3 were included (Bentsen et al.,
2013; Berger et al., 2007; Emsley et al., 2002, 2006, 2008; Fenton
et al., 2001; Manteghiy et al., 2008; Peet et al., 2001; Peet and
Horrobin, 2002; Toktam et al., 2010; Vaddadi et al., 1989), and one
combined omega-3 with vitamins E and C (Bentsen et al., 2013). In
studies combining antipsychotics with omega-3 PUFA, one (from five)
study on negative symptoms in schizophrenia found some positive ef-
fect (in patients using clozapine; Peet and Horrobin, 2002), two (from
four) found some positive effect on positive symptoms (Peet et al.,© 2018 Wolters Kluwer Health, Inc. All rights reserved.2001; Peet and Horrobin, 2002; one only in patients using clozapine
[Peet and Horrobin, 2002]), one (from two) on cognitive symptoms
(Vaddadi et al., 1989), none (from three) on depressive symptoms,
and four (from eight) on general psychopathology (Emsley et al.,
2002; Peet et al., 2001; Peet and Horrobin, 2002; Vaddadi et al.,
1989; one only in patients using clozapine [Peet and Horrobin,
2002]). One (from one) study on omega-3 PUFAwithout antipsychotics
reported a decrease of positive symptoms (Peet et al., 2001). Three
(from six) reported less adverse effects of antipsychotics (EPS and/or
dyskinesia) (Berger et al., 2007; Emsley et al., 2002; Vaddadi et al.,
1989). Two studies reported less use of antipsychotics in the omega-3
PUFA group (Berger et al., 2007; Peet et al., 2001). One study
reported an increase in positive symptoms by omega-3 (EPA), but
only among those with low levels of red blood cell PUFA. This effect
disappeared when EPA was combined with vitamin E and vitamin C
(Bentsen et al., 2013). Some nonsevere adverse effects of omega-3
PUFA were reported, such as mild gastrointestinal problems and
increased bleeding time.
(ii) Glutamate
Nine RCTs on glycine (Buchanan et al., 2007; Diaz et al., 2005;
Evins et al., 2000; Heresco et al., 1996, 2004; Heresco-Levy et al.,
1999; Javitt et al., 1994, 2001; Potkin et al., 1999), eight on D-serine
(D'Souza et al., 2013; Ermilov et al., 2013; Heresco-Levy et al.,
2005; Lane et al., 2005, 2010; Tsai et al., 1998, 1999; Weiser
et al., 2012), ten on D-cycloserine (Buchanan et al., 2007; Cain et al.,
2014; Duncan et al., 2004; Goff et al., 2005, 2008; Gottlieb et al.,
2011; Heresco-Levy et al., 2002; Rosse et al., 1996; Van Berckel
et al., 1999; Yurgelun-Todd et al., 2005), one on D-alanine (Tsai et al.,
2006), five on sarcosine (Lane et al., 2005, 2006, 2008, 2010; Tsai
et al., 2004), and two on NAC (Berk et al., 2008; Lavoie et al., 2008)
were included.
Glycine improved negative symptoms when combined with an-
tipsychotics in six (from seven) studies (Buchanan et al., 2007; Heresco
et al., 1996, 2004; Heresco-Levy et al., 1999; Javitt et al., 1994, 2001),
but not when combined with clozapine (two studies) (Potkin et al.,
1999; Evins et al., 2000). Positive symptoms improved in one study
(Heresco et al., 2004), worsened in another (with clozapine) (Potkin
et al., 1999), and did not change in five (from seven) studies (Diaz et al.,
2005; Evins et al., 2000; Heresco et al., 1996; Heresco-Levy et al.,
1999; Javitt et al., 1994); cognitive improvement was shown in four
(Heresco et al., 1996, 2004; Heresco-Levy et al., 1999; Heresco et al.,
2004; Javitt et al., 2001) and no change in two (from seven) studies
(Buchanan et al., 2007; Evins et al., 2000); depressive symptoms
diminished in four (from four) studies (Heresco et al., 1996,
2004; Heresco-Levy et al., 1999; Javitt et al., 2001); and improvement
of general psychopathology was shown in three (from eight)
studies (Heresco et al., 1996, 2004; Heresco-Levy et al., 1999).
No adverse effects of glycine were reported, except some mild
gastrointestinal complaints.
D-Serine was shown to improve positive, negative, and cognitive
symptoms and general psychopathology in two (from six) studies when
added to antipsychotics (Heresco-Levy et al., 2005; Tsai et al., 1998).
The three largest studieswith the highest Jadad score did not showa sig-
nificant effect of D-serine on any symptom (Lane et al., 2005; Lane
et al., 2010; Weiser et al., 2012). In four (from six) studies, D-serine
did not improve adverse effects of antipsychotics (Lane et al., 2005,
2010; Tsai et al., 1998, 1999). Insomnia, weight gain, palpitations,
and other adverse effects of D-serine were reported. One study found
improvement by D-serine without antipsychotics, but this was signifi-
cantly less compared with the improvement in the olanzapine group;
D-serine, however, caused less adverse effects (Ermilov et al., 2013).
D-Cycloserine showed an improvement of negative symptoms in
three (from nine) studies when added to antipsychotics (Goff et al.,
2008; Heresco-Levy et al., 2002; Yurgelun-Todd et al., 2005); somewww.jonmd.com 93
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worsening in another study (from seven) (Van Berckel et al., 1999);
and little or no effect on cognitive and depressive symptoms or general
psychopathology and no improvement of adverse effects of antipsychotics
was shown. Five (from five) studies found no improvement of
adverse effects of antipsychotics (Buchanan et al., 2007; Duncan
et al., 2004; Goff et al., 2005; Heresco-Levy et al., 2002; Van Berckel
et al., 1999). No studies were reported on D-cycloserine without
antipsychotics. No adverse effects of D-cycloserine were reported.
The only study on D-alanine reported positive effects when
added to antipsychotics on negative, positive, cognitive, and general
symptoms, but no effect on depressive symptoms (Tsai et al., 2006).
No effect on adverse effects of antipsychotics was found. Adverse ef-
fects of D-alanine (insomnia and nausea) were reported.
All three studies combining sarcosine with antipsychotics (not
clozapine) found positive effects in almost all symptom domains
(Lane et al., 2005, 2010; Tsai et al., 2004). When combined with cloza-
pine (one study), no treatment effects were found (Lane et al., 2006). In
addition, when given without antipsychotics (one study), sarcosine did
not improve symptoms (Lane et al., 2008). Sarcosine did not improve
adverse effects of antipsychotics in four (from four) studies (Lane
et al., 2005, 2006, 2010; Tsai et al., 2004). Adverse effects of sarcosine
included weight gain, insomnia, palpitations, dizziness, and sedation.
One large study on NAC added to antipsychotics reported im-
proved positive symptoms but no improvement of negative, cognitive,
or general symptoms and no improvement of adverse effects of antipsy-
chotics (Berk et al., 2008), whereas one small study found some im-
provement of cognitive symptoms (Lavoie et al., 2008). The large
study (Berk et al., 2008) reported that there were no adverse effects,
and in the small study (Lavoie et al., 2008), occurrence of any adverse
effect was not mentioned.
(iii) Eastern (Chinese and Ayurvedic) Herbs
Many studies on Eastern herbs were found, but only six had
a Jadad score of three or higher (Chen et al., 2008a, 2008b, 2009; Mahal
et al., 1976; Mundewadi et al., 2008; Naidoo, 1956). One old study on
reserpine found “clinical improvement” after 11 weeks compared with
placebo in 80 patients not treated with antipsychotics but with
electroconvulsice therapy (Naidoo, 1956). Several adverse effects were
reported: nasal congestion, periorbital edema, diarrhea, epigastric pain,
salivating, pseudo-Parkinsonian state, severe headaches, and deep pains
in limbs. Another old study (Mahal et al., 1976) found positive effects
of brahmyadiyoga without antipsychotics compared with placebo
and equal to chlorpromazin in 136 patients with schizophrenia
(Mahal et al., 1976); no adverse effects were reported. Four (from
six) more recent studies found significant effects on general psychopa-
thology when adding ayurvedic herbs (reserpine: one study [Naidoo,
1956]; bacopa monnieri and nardostachys jatamansi: one study
[Mundewadi et al., 2008]; a mixture of 13 Chinese herbs: two studies
[Chen et al., 2008a, 2008b, 2009]) to antipsychotics.
The ayurvedic herbs were compared with 10mg of olanzapine in
a 76-week noninferiority study in 200 patients. No statistically signifi-
cant differences were found between both groups examining improve-
ment of positive and negative symptoms and general psychopathology.
The ayurvedic group had less weight gain (Mundewadi et al., 2008).
Two large studies by Chen et al. (2008a, 2008b, 2009) of a mixture of
13 Chinese herbs found an improvement on general psychopathology.
When kidney yang was added to risperidone, an improvement on cogni-
tive and depressive symptoms was found in one study (from two) (Chen
et al., 2008a, 2009). One study found no effect of the Chinese herb
sarsasapogenin compared with placebo when added to risperidone on
positive, negative, and cognitive symptoms or general psychopathology
in 90 patients during 8 weeks (Xiao et al., 2011). Many different
nonsevere adverse effects were reported (e.g., gastrointestinal, drowsi-
ness, and insomnia).94 www.jonmd.com(iv) B Vitamins
Nineteen RCTs on B vitamins added to antipsychotics (Ananth
et al., 1972, 1973; Deutsch et al., 1977; Godfrey et al., 1990; Hill
et al., 2011; Joshi, 1982; Kline et al., 1967; Lerner et al., 2001, 2002,
2004, 2007; Levine et al., 2006; McGrath et al., 1972; Meltzer et al.,
1969; Miodownik et al., 2006; Petrie et al., 1981; Ramsay et al.,
1970; Roffman et al., 2013; Sacks et al., 1989; Wittenborn et al., 1973)
and one on B3 without antipsychotics (Greenbaum 1970) were found.
B1 showed some positive effect on general psychopathology (when
combined with B6 and B12) in one study (Joshi, 1982) and on positive
and negative symptoms in another (Sacks et al., 1989). B3 showed im-
proved general psychopathology in three (from nine) studies (Ananth
et al., 1972, 1973; Petrie et al., 1981). B6 improved general psychopa-
thology in four (from five) studies (Ananth et al., 1973; Lerner et al.,
2004; Miodownik et al., 2006; Petrie et al., 1981). In one study, general
psychopathology improved after the administration of methylfolate
(Godfrey et al., 1990). One study reported no effect of B9 (folic acid)
(Hill et al., 2011). Another study showed a positive effect of combined
B6, B9, and B12 on positive, negative, and cognitive symptoms
(Levine et al., 2006). Yet, another study showed improved negative
symptoms by adding B9 (folic acid) and B12 to antipsychotics, but
only in those with a specific genotype (Roffman et al., 2013). B6 im-
proved extrapyramidal adverse effects of antipsychotics (TD and neuro-
leptic induced akathisia) in four (from four) studies (Lerner et al., 2001,
2002, 2004, 2007; Miodownik et al., 2006). In one study on B3 in 57
children without antipsychotics, cognition and general psychopathol-
ogy had not improved after 6 months (Greenbaum, 1970). Most B vita-
mins induced modest adverse effects, especially skin flushing and
abnormal liver function induced by vitamin B3 and B6.(v) Antioxidants
TwoRCTs onvitamin Cwere found (Bhavani et al., 1962; Dakhale
et al., 2005). One reported improved general psychopathology and re-
duced adverse effects (reduced serummalondialdehyde; a lipid peroxida-
tion product) when added to olanzapine (10 mg), quetiapine (200 mg), or
ziprasidone (40mg) after 8 weeks (Dakhale et al., 2005). One studywith-
out antipsychotics found no effect on cognition or motor functioning
after 10 days (Bhavani et al., 1962). Both studies reported no adverse
effects of vitamin C.
Four studies on ginkgo biloba were found (Zhang et al.,
2001a, 2001b, 2006, 2011b; Zhou et al., 1999). Three (from four)
studies found improved positive symptoms (Zhang et al., 2001a,
2001b, 2006, 2011b; Zhou et al., 1999), two (from three) found im-
proved general psychopathology (Zhang et al., 2001a; Zhou et al.,
1999), and four (from four) reported no improvement of negative symp-
toms when added to antipsychotics (Zhang et al., 2001a, 2001b, 2006,
2011a; Zhou et al., 1999). In all four studies, adverse effects of antipsy-
chotics improved (behavioral toxicity, symtoms of nervous system, and
TD). No adverse effects of ginkgo were reported.
Thirteen studies of vitamin E were found (Adler et al., 1993,
1999; Akhtar et al., 1993; Dabiri et al., 1994; Dorevitch et al., 1997a,
1997b; Egan et al., 1992; Elkashef et al., 1990; Lam et al., 1994; Lohr
and Caligiuri, 1996; Salmasi et al., 2009; Schmidt et al., 1991; Shriqui
et al., 1992). Six (from 13) studies for reducing EPSs, while using anti-
psychotics, showed a decrease of TD (Adler et al., 1993; Akhtar et al.,
1993; Dabiri et al., 1994; Egan et al., 1992; Elkashef et al., 1990; Lohr
and Caligiuri 1996) and EPS (one study; Elkashef et al., 1990), and those
with shorter duration of TD seemed to improve more; no adverse effects
of vitamin E were reported, except mild diarrhea in two studies. Five
(from five) reported no effect on general psychopathology (Adler
et al., 1999; Dorevitch et al., 1997a; Elkashef et al., 1990; Lam
et al., 1994; Lohr and Caligiuri, 1996). One study of melatonin for TD
reported a decrease of TD and no adverse effects (Shamir et al., 2001).© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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Agents that did not fit in the five aforementioned categories were
classified in this residual category. A total of 16 high-quality RCTs have
been performed on multivitamins (Altman et al., 1973; Vaughan and
McConaghy, 1999), hormones (DHEA; Nachshoni et al., 2005; Ritsner,
2010; Ritsner et al., 2006; Strous et al., 2003, 2007), pregnenolone
(PREG; Ritsner, 2010), estradiol (Akhondzadeh et al., 2003; Kulkarni
et al., 2008, 2011), protilerin (thyrotropin-releasing hormone)
(Prange, 1979), testosterone (Ko et al., 2008), inositol (Levine et al.,
1994), gamma-hydroxybutyrate (GHB; Levy et al., 1983; Schulz
et al., 1981) and des-tyr-gamma-endorphin (Verhoeven et al., 1979).
Two (from five) studies onDHEA added to antipsychotics showed
improvement of negative symptoms (Ritsner et al., 2006; Strous et al.,
2003), two (from three) on positive symptoms (Ritsner, 2010; Ritsner
et al., 2006), one (from three) on cognition (Ritsner et al., 2006), two
(from two) on depression (Ritsner et al., 2006; Strous et al., 2003), and
one (from four) on general functioning (Strous et al., 2003). Three (from
four) improved adverse effects of drugs (Nachshoni et al., 2005; Ritsner,
2010; Strous et al., 2007). In one study of 30 patients with schizophrenia,
using either 5 g of 1% testosterone gel or a placebo added to a fixed dos-
age of antipsychotic medication over a period of 4 weeks, negative symp-
toms improved without adverse effects (Ko et al., 2008). One (from one)
small study (N = 12) on protilerin found improved general psychopathol-
ogy (Prange, 1979). Three (from three) studies on estradiol showed
improvement of general psychopathology (Akhondzadeh et al.,
2003; Kulkarni et al., 2008, 2011), two (from three) of positive symptoms
(Akhondzadeh et al., 2003; Kulkarni et al., 2008), one (from one) of
improved cognition (Kulkarni et al., 2008), and none (from three) of
negative symptoms.
One (from one) small study (N = 14) on inositol found no effect
on positive or negative symptoms (Levine et al., 1994). Two (from two)
studies on GHB found no improvement of general psychopathology
(Levy et al., 1983; Schulz et al., 1981). One (from one) very small
(N = 6) study on des-tyr-gamma-endorphin found improvement on gen-
eral psychopathology and positive symptoms (Verhoeven et al., 1979).
No serious adverse effects of these agents were reported.
One study (of two) on artemisinin (a natural medicine against
malaria) found a significant effect on negative symptoms and clinical
global impression, but no effect on positive or cognitive symptoms
or on general psychopathology in first-episode treatment-naive
patients that were treated with risperidone (Dickerson et al.,
2011; Wang et al., 2014). The study of Dickerson et al. (2011)
did not demonstrate clinical benefit of adjunctive artemisinin for
schizophrenia symptoms.
DISCUSSION
This review describes the effects of natural agents in the treat-
ment of psychotic disorders and of undesired effects of antipsychotics.
Some studies suggest that glycine, sarcosine, NAC, several Chinese and
ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6may be effec-
tive for psychotic symptoms when added to antipsychotics (glycine not
when added to clozapine). We found inconclusive or no evidence
for omega-3 fatty acids, D-serine, D-alanine, D-cycloserine, other
B vitamins, vitamin C, DHEA, PREG, inositol, GHB, and des-
tyr-gamma-endorphin when added to antipsychotics. Reserpine with-
out antipsychotics seemed effective in one old study but was poorly
tolerated. Ayurvedic herbs seemed equally effective as olanzapine in
only one study. Other agents as monotherapy (vitamin B3, vitamin C,
sarcosine, glycine, and protilerin) were not effective or had only been
tested in single or small trials. For alleviation of adverse effects, ginkgo
and vitamin B6 seemed effective for TD and neuroleptic induced
akathisia (NIA). The evidence for reducing some adverse effects
of antipsychotics by omega-3 fatty acids, melatonin, and DHEA
was inconclusive.© 2018 Wolters Kluwer Health, Inc. All rights reserved.Apart from reserpine, all natural compounds studied caused no or
mild undesired adverse effects. There is inconclusive evidence for im-
proved outcome by combining omega-3 fatty acids with antipsychotics
in schizophrenia. Earlier reviews reported similar conclusions (Boskovic
et al., 2011; Irving et al., 2006; Tsalamanios et al., 2006). A meta-
analysis of randomized placebo controlled trails showed a modest, non-
significant, beneficial effect of fatty acids in schizophrenia (Fusar-Poli
and Berger, 2012).
Glycine and sarcosine combined with antipsychotics may reduce
negative symptoms, but not when combined with clozapine and neither
as monotherapy. Inconclusive evidence was found for D-cycloserine
and D-serine on clinical improvement. Our results concurwith two reviews
(Singh and Singh, 2011; Tsai and Lin, 2010) and are in line with a
Cochrane review (Tiihonen andWahlbeck, 2006). Conflicting results from
studies on drugs targeting the glutamate/NMDA systemmay be explained
by complicated dose-effect relationships, as recently found in studies with
the GlyT-1 transporter antagonist bitopertin (Umbricht et al., 2013).
By adding Chinese or ayurvedic herbs to antipsychotics,
general psychopathology may improve. One study (of two) on
artemisinin (a natural medicine against malaria) found a signifi-
cant effect on negative symptoms and clinical global impression,
but no effect on positive or cognitive symptoms or on general psy-
chopathology in first-episode treatment-naive patients who were
treated with risperidone (Wang et al., 2014; Dickerson et al.,
2011). The study of Dickerson et al. (2011) did not demonstrate
clinical benefit of adjunctive artemisinin for schizophrenia symp-
toms. Rathbone et al. (2007) state that “the results suggest that
combining Chinese herbal medicine with antipsychotics is benefi-
cial.” Another Cochrane review (Agarwal et al., 2007) concludes
that “ayurvedic medication may have some effects for treatment
of schizophrenia, but has been evaluated only in a few small pio-
neering trials.” These results need further exploration and pharma-
cological differentation, as Chinese and ayurvedic herbs include
hundreds of species combined in thousands of different combina-
tions and are prescribed in a fundamentally different way than
Western medicines (Clifford, 1994; Kaptchuck, 2000). The com-
bined approach using knowledge from both conventional and
Chinese medicine seems promising, as it may lead to innovation
(Van der Greef, 2011) and possibly to improved outcomes (Zhang
et al., 2011b).
Inconsistent beneficial outcomes of studies on B vitamins were
identified, especially when given as a combination of B1, B3, B6, B9,
and/or B12with antipsychotics. One review concluded that no adequate
support for the efficacy of B vitamins in schizophrenia can be identified
(Kleijnen and Knipschild, 1991). Most studies with positive effects in
our review, however, were published after the aforementioned review
was published. Most convincing evidence was found for vitamin B6
added to antipsychotics, shown to be effective in diminishing general
psychopathology and TD.
The findings on the efficacy of vitamin C for schizophrenia in
only two RCTs were inconsistent, hindering definite conclusions. The
efficacy of vitamin E on TD remains inconclusive, as only half of the
included studies found some positive results. Even so, a meta-analysis
by Boskovic et al. (2011) claimed, “Vitamin E could potentially improve
TD.” This may be due to the finding that those with a short history of
TD tend to improve more than those with a longer history of TD. A
Cochrane review in 2011 (Soares et al., 2011) came to a similar conclusion:
“small trials of limited quality suggest that vitamin E may protect against
deterioration of TD. There is no evidence that vitamin E improves symp-
toms of this problematic and disfiguring condition once established.”
Ginkgo biloba seems to benefit patients with schizophrenia in
several ways when added to antipsychotics. Several studies sug-
gested evidence for improving symptoms in various domains, espe-
cially an effect on positive symptoms and the reduction of adverse
effects of antipsychotics.www.jonmd.com 95
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diminishing TD (Shamir et al., 2001). As TD is difficult to investigate be-
cause of the fluctuating symptom severity, this study needs replication.
Some inconsistent evidence was found on improved outcomes
by several hormones (DHEA, PREG, and testosterone) in schizophre-
nia, not allowing final conclusions. A Cochrane review on DHEA/
testosterone drew a similar conclusion (Elias and Kumar, 2007). For es-
tradiol, a Cochrane review reported no convincing evidence over pla-
cebo (Chua et al., 2005). Since then, two studies found that estradiol
improves positive (but not negative) symptoms and general psychopa-
thology in schizophrenia when added to antipsychotics (Kulkarni
et al., 2008, 2011), however only in women of childbearing age. There-
fore, using estradiol in schizophrenia warrants further study.Limitations
There are several methodological limitations. First, the wide
scope of this review allows only general descriptions of included stud-
ies in six domains. Second, it is unclear towhich extent our findings are
influenced by publication bias, in favor of publication of studies with
positive results. Third, we used the Jadad score to select only RCTs of
high quality (with a score of three or higher, as is in accordance with
other reviews [e.g., see Thirthalli et al., 2016]). However, the Jadad
score is not a perfect tool because it does not judge the selection of sub-
jects, the sample size and power, and the quality of the data analyses.
Therefore, RCTs with a Jadad score of 3 or higher might still have
methodological weaknesses, which hamper drawing firm conclu-
sions. Fourth, some studies (e.g., Bhavani et al., 1962; Greenbaum
1970; Naidoo, 1956) were done in the pre–Diagnostic and Statistical
Manual of Mental Disorders, 3rd Edition (DSM-3) era, when standards
of care and diagnostics may have been of lower quality than nowadays,
which hampers interpretation of their results. Fifth, in most of the stud-
ies included, effect sizes were not provided nor was it possible to calcu-
late them, which makes it difficult to compare the results or to estimate
the clinical relevance of some of the findings. Sixth, it cannot be ruled
out that some of the studies were underpowered, which might have
hampered finding a significant effect.Clinical Implications
Clinicians need to be aware that patients often use natural medi-
cines without medical prescription, whereas some patients assume that
natural is better than chemical and causes fewer adverse effects. Al-
though beneficial effects may occur, this is certainly not always true.
Some natural agents that may be suggested for treatment of psychotic
disorders are toxic to humans (Topliss et al., 2002), and some herbal
medicines can cause adverse effects or interact with medication
(Ernst, 2003b). Only 3% of the user population is aware of the potential
risks of interactions between herbs and prescription medication (Walter
and Rey, 1999). From a medical perspective, it is therefore important to
know what patients buy and try. Another concern are the media reports
on contamination of Chinese herbs with heavy metals. However, after
investigation of 334 samples, Harris et al. (2011) conclude that “the vast
majority (95%) of medications in this study contained levels of heavy
metals or pesticides that would be of negligible concern.” Because of
these concerns, patients want their medical doctors to advise them on
complementary (or natural) medicines (Gray et al., 1998; Hoenders
et al., 2006). The World Health Organization (2013) has repeatedly ad-
vised its member states to “formulate national policy and regulation for
the proper use of CAM and its integration into national health care sys-
tems; establish regulatory mechanisms to control the safety and quality
of products and of CAM practice; create awareness about safe and ef-
fective CAM therapies among the public and consumers” and “promote
therapeutically sound use of appropriate Traditional Medicine by96 www.jonmd.compractitioners and consumers.” Respecting patients' opinions and informing
them may also improve the therapeutic relationship (Stevinson, 2001) and
thus enhance treatment outcome (Gill, 2013; Koenig, 2000), which de-
pends on the quality of the therapeutic alliance (Baldwin et al., 2007).
This review gives clinicians and patients an overview of the re-
sults of RCTs, which fit a minimal level of quality (minimum Jadad
score of 3), on the efficacy and safety of natural medicines for psychotic
disorders. However, many questions about clinical use (e.g., dosage,
safety, interactions, and quality) remain unanswered.ACKNOWLEDGMENTS
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